• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13D/A filed by Alzamend Neuro Inc. (Amendment)

    4/28/22 7:00:19 AM ET
    $ALZN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ALZN alert in real time by email
    SC 13D/A 1 g427220sc13da2.htm AMENDMENT NO. 2

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13D

    (Rule 13d-101)

     

    INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT

    TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO

    § 240.13d-2(a)

     

    (Amendment No. 2)1

     

    Alzamend Neuro, Inc.

    (Name of Issuer)

     

    Common Stock, par value $0.0001 per share

    (Title of Class of Securities)

     

    02262M308

    (CUSIP Number)

     

    MILTON C. AULT, III

    c/o BITNILE HOLDINGS, INC.

    11411 Southern Highlands Parkway, Suite 240

    Las Vegas, NV 89141

    (949) 444-5464

    (Name, Address and Telephone Number of Person

    Authorized to Receive Notices and Communications)

     

    April 26, 2022

    (Date of Event Which Requires Filing of This Statement)

     

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box o.

     

    Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See § 240.13d-7 for other parties to whom copies are to be sent.

     

    _______________

    1             The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

     

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     1 
     

     

    1

    NAME OF REPORTING PERSON

     

    MILTON C. AULT, III

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP  

    (a) x

    (b) o

    3

    SEC USE ONLY

     

    4

    SOURCE OF FUNDS

     

    AF, OO

    5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e) o
    6

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    U.S.A.

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    7

    SOLE VOTING POWER

     

    2,500,000(1)

    8

    SHARED VOTING POWER

     

    39,868,318(2) (3)

    9

    SOLE DISPOSITIVE POWER

     

    2,500,000(1)

    10

    SHARED DISPOSITIVE POWER

     

    39,868,318 (2) (3)

    11

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    42,368,318

    12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES o
    13

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

    43.2%

    14

    TYPE OF REPORTING PERSON

     

    IN

     

    (1) Represents shares of Common Stock.
    (2) Represents (i) 16,667 shares of Common Stock underlying currently exercisable warrants held by BitNile Holdings, Inc., (ii) 14,942,984 shares of Common Stock held by Ault Life Sciences, Inc., (iii) 10,000,000 shares of Common Stock held by Ault Life Sciences Fund, LLC, (iv) 5,000,000 shares of Common Stock underlying currently exercisable warrants held by Ault Life Sciences Fund, LLC, (v) 9,666,667 shares of Common Stock held by Digital Power Lending, LLC, (vi) 17,000 shares of Common Stock underlying currently exercisable call options (right to buy) held by Digital Power Lending, LLC and (vii) 225,000 shares of Common Stock held by Ault Alpha LP.
    (3) Excludes 3,333,333 shares of Common Stock underlying currently exercisable warrants held by Digital Power Lending, LLC due to a beneficial ownership blocker limitation provision contained therein.

     

     2 
     

     

    1

    NAME OF REPORTING PERSON

     

    WILLIAM B. HORNE

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP  

    (a) x

    (b) o

    3

    SEC USE ONLY

     

    4

    SOURCE OF FUNDS

     

    OO

    5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e) o
    6

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    U.S.A.

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    7

    SOLE VOTING POWER

     

    2,661,458(1)

    8

    SHARED VOTING POWER

     

    - 0 -

    9

    SOLE DISPOSITIVE POWER

     

    2,661,458 (1)

    10

    SHARED DISPOSITIVE POWER

     

    - 0 -

    11

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    2,661,458

    12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES o
    13

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

    2.8%

    14

    TYPE OF REPORTING PERSON

     

    IN

     

    (1) Represents (i) 500,000 shares of Common Stock, and (ii) 2,161,458 shares of Common Stock underlying stock options currently exercisable or exercisable within 60 days.

     

     3 
     

     

    1

    NAME OF REPORTING PERSON

     

    HENRY C.W. NISSER

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP  

    (a) x

    (b) o

    3

    SEC USE ONLY

     

    4

    SOURCE OF FUNDS

     

    OO

    5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e) o
    6

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Sweden

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    7

    SOLE VOTING POWER

     

    963,542(1)

    8

    SHARED VOTING POWER

     

    - 0 -

    9

    SOLE DISPOSITIVE POWER

     

    963,542 (1)

    10

    SHARED DISPOSITIVE POWER

     

    - 0 -

    11

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    963,542

    12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES
    13

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

    1.0%

    14

    TYPE OF REPORTING PERSON

     

    IN

     

    (1) Represents 963,542 shares of Common Stock underlying stock options currently exercisable or exercisable within 60 days.

     

     4 
     

     

    1

    NAME OF REPORTING PERSON

     

    KENNETH S. CRAGUN

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP  

    (a) x

    (b) o

    3

    SEC USE ONLY

     

    4

    SOURCE OF FUNDS

     

    OO

    5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e) o
    6

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    U.S.A.

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    7

    SOLE VOTING POWER

     

    1,312,500(1)

    8

    SHARED VOTING POWER

     

    - 0 -

    9

    SOLE DISPOSITIVE POWER

     

    1,312,500 (1)

    10

    SHARED DISPOSITIVE POWER

     

    - 0 -

    11

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    1,312,500

    12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES
    13

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

    1.4%

    14

    TYPE OF REPORTING PERSON

     

    IN

     

    (1) Represents 1,312,500 shares of Common Stock underlying stock options currently exercisable or exercisable within 60 days.

     

     5 
     

     

    1

    NAME OF REPORTING PERSON

     

    DAVID J. KATZOFF

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP  

    (a) x

    (b) o

    3

    SEC USE ONLY

     

    4

    SOURCE OF FUNDS

     

    PF, OO

    5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e) o
    6

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    U.S.A.

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    7

    SOLE VOTING POWER

     

    1,079,083 (1)

    8

    SHARED VOTING POWER

     

    - 0 -

    9

    SOLE DISPOSITIVE POWER

     

    1,079,083 (1)

    10

    SHARED DISPOSITIVE POWER

     

    - 0 -

    11

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    1,079,083

    12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES
    13

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

    1.2%

    14

    TYPE OF REPORTING PERSON

     

    IN

     

    (1) Represents (i) 18,000 shares of Common Stock, (ii) 9,000 shares of Common Stock underlying currently exercisable warrants and (iii) 1,052,093 shares of Common Stock underlying stock options currently exercisable or exercisable within 60 days.

     

     6 
     

     

    1

    NAME OF REPORTING PERSON

     

    BITNILE HOLDINGS, INC.

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP  

    (a) x

    (b) o

    3

    SEC USE ONLY

     

    4

    SOURCE OF FUNDS

     

    AF

    5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e) o
    6

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    7

    SOLE VOTING POWER

     

    16,667(1)

    8

    SHARED VOTING POWER

     

    9,683,667(2) (3)

    9

    SOLE DISPOSITIVE POWER

     

    16,667(1)

    10

    SHARED DISPOSITIVE POWER

     

    9,683,667(2) (3)

    11

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    9,700,334

    12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES o
    13

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

    10.4%

    14

    TYPE OF REPORTING PERSON

     

    CO

     

    (1)Represents 16,667 shares of Common Stock underlying currently exercisable warrants.
    (2) Represents (i) 9,666,667 shares of Common Stock held by Digital Power Lending, LLC and (ii) 17,000 shares of Common Stock underlying currently exercisable call options (right to buy) held by Digital Power Lending, LLC.
    (3) Excludes 3,333,333 shares of Common Stock underlying currently exercisable warrants held by Digital Power Lending, LLC due to a beneficial ownership blocker limitation provision contained therein.

     

     7 
     

     

    1

    NAME OF REPORTING PERSON

     

    AULT LIFE SCIENCES, INC.

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP  

    (a) x

    (b) o

    3

    SEC USE ONLY

     

    4

    SOURCE OF FUNDS

     

    WC

    5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e) o
    6

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    7

    SOLE VOTING POWER

     

    - 0 -

    8

    SHARED VOTING POWER

     

    14,942,984

    9

    SOLE DISPOSITIVE POWER

     

    - 0 -

    10

    SHARED DISPOSITIVE POWER

     

    14,942,984

    11

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    14,942,984

    12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES o
    13

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

    16.1%

    14

    TYPE OF REPORTING PERSON

     

    CO

     

     8 
     

     

    1

    NAME OF REPORTING PERSON

     

    AULT LIFE SCIENCES FUND, LLC

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP  

    (a) x

    (b) o

    3

    SEC USE ONLY

     

    4

    SOURCE OF FUNDS

     

    WC, OO

    5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e) o
    6

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    7

    SOLE VOTING POWER

     

    - 0 -

    8

    SHARED VOTING POWER

     

    15,000,000(1)

    9

    SOLE DISPOSITIVE POWER

     

    - 0 -

    10

    SHARED DISPOSITIVE POWER

     

    15,000,000(1)

    11

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    15,000,000

    12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES o
    13

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

    15.3%

    14

    TYPE OF REPORTING PERSON

     

    OO

     

    (1)Represents (i) 10,000,000 shares of Common Stock held by Ault Life Sciences Fund, LLC and (ii) 5,000,000 shares of Common Stock underlying currently exercisable warrants held by Ault Life Sciences Fund, LLC.

     

     9 
     

     

    1

    NAME OF REPORTING PERSON

     

    DIGITAL POWER LENDING, LLC

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP  

    (a) x

    (b) o

    3

    SEC USE ONLY

     

    4

    SOURCE OF FUNDS

     

    WC, OO

    5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e)o
    6

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    California

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    7

    SOLE VOTING POWER

     

    - 0 -

    8

    SHARED VOTING POWER

     

    9,683,667(1) (2)

    9

    SOLE DISPOSITIVE POWER

     

    - 0 -

    10

    SHARED DISPOSITIVE POWER

     

    9,683,667(1) (2)

    11

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    9,683,667

    12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES o
    13

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

    10.4%

    14

    TYPE OF REPORTING PERSON

     

    OO

     

    (1) Represents (i) 9,666,667 shares of Common Stock held by Digital Power Lending, LLC and (ii) 17,000 shares of Common Stock underlying currently exercisable call options (right to buy) held by Digital Power Lending, LLC.
    (2) Excludes 3,333,333 shares of Common Stock underlying currently exercisable warrants held by Digital Power Lending, LLC due to a beneficial ownership blocker limitation provision contained therein.

     

      10 
     

     

    1

    NAME OF REPORTING PERSON

     

    AULT ALPHA LP

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP  

    (a) x

    (b) o

    3

    SEC USE ONLY

     

    4

    SOURCE OF FUNDS

     

    WC

    5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e)o
    6

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    7

    SOLE VOTING POWER

     

    - 0 -

    8

    SHARED VOTING POWER

     

    225,000 (1)

    9

    SOLE DISPOSITIVE POWER

     

    - 0 -

    10

    SHARED DISPOSITIVE POWER

     

    225,000 (1)

    11

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    225,000

    12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES o
    13

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

    Less than 1%

    14

    TYPE OF REPORTING PERSON

     

    OO

     

    (1) Represents 225,000 shares of Common Stock held by Ault Alpha LP.

     

     11 
     

     

    The following constitutes Amendment No. 2 (“Amendment No. 2”) to the Schedule 13D filed by the undersigned on June 25, 2021 and amended August 4, 2021 (the “Schedule 13D”). This Amendment No. 2 amends the Schedule 13D as specifically set forth herein. Except as otherwise specified in this Amendment No. 2, all items in the Schedule 13D are unchanged. All capitalized terms used in this Amendment No. 2 and not otherwise defined herein have the meanings ascribed to such terms in the Schedule 13D.

     

    Item 1. Security and Issuer.

     

    This statement relates to the Common Stock, $0.0001 par value per share (the “Shares”), of Alzamend Neuro, Inc., a Delaware corporation (the “Issuer”). The address of the principal executive offices of the Issuer is 3500 Lenox Rd. NE, Suite 1500, Atlanta, GA 30326.

     

    Item 2. Identity and Background.

     

    (a) This statement is filed by:

     

    (i) Milton C. Ault, III, Chairman Emeritus of the Issuer, Founder and Executive Chairman of BitNile Holdings, Inc., Chief Executive Officer and Director of Ault Life Sciences, Inc., Managing Member of Ault Life Sciences Fund, LLC and Manager of the general partner of Ault Alpha LP;

     

    (ii) William B. Horne, Chairman of the Board of Directors of the Issuer, Chief Executive Officer and Director of BitNile Holdings, Inc. and Chief Financial Officer and Director of Ault Life Sciences, Inc.;

     

    (iii) Henry C.W. Nisser, Executive Vice President, General Counsel and Director of the Issuer, President, General Counsel and Director of BitNile Holdings, Inc. and President and Director of Ault Life Sciences, Inc.;

     

    (iv) Kenneth S. Cragun, Senior Vice President of Finance of the Issuer, Chief Financial Officer of BitNile Holdings, Inc. and Chief Accounting Officer of Ault Life Sciences, Inc.;

     

    (v) David Katzoff, Chief Operating Officer of the Issuer and Manager of Digital Power Lending, LLC;

     

    (vi) BitNile Holdings, Inc. (formerly, Ault Global Holdings, Inc.), a Delaware corporation, with respect to the Shares beneficially owned by it through its subsidiary Digital Power Lending, LLC;

     

    (vii) Ault Life Sciences, Inc., a Delaware corporation, with respect to the Shares directly and beneficially owned by it;

     

    (viii) Ault Life Sciences Fund, LLC, a Delaware limited liability company, with respect to the Shares directly and beneficially owned by it;

     

    (ix) Digital Power Lending, LLC, a California limited liability company, with respect to the Shares directly and beneficially owned by it; and

     

    (x) Ault Alpha LP, a Delaware limited partnership, with respect to the Shares directly and beneficially owned by it.

     

     12 
     

     

    Each of the foregoing is referred to as a “Reporting Person” and collectively as the “Reporting Persons.” Each of the Reporting Persons is party to that certain Joint Filing Agreement, attached hereto as Exhibit 99.1. Accordingly, the Reporting Persons are hereby filing a joint Schedule 13D.

     

    Set forth on Schedule A annexed hereto (“Schedule A”) is the name and present principal occupation or employment, principal business address and citizenship of the executive officers and directors of BitNile Holdings, Inc. To the best of the Reporting Persons’ knowledge, except as otherwise set forth herein, none of the persons listed in Schedule A beneficially owns any securities of the Issuer or is a party to any contract, agreement or understanding required to be disclosed herein.

     

    Set forth on Schedule B annexed hereto (“Schedule B”) is the name and present principal occupation or employment, principal business address and citizenship of the executive officers and directors of Ault Life Sciences, Inc. To the best of the Reporting Persons’ knowledge, except as otherwise set forth herein, none of the persons listed in Schedule B beneficially owns any securities of the Issuer or is a party to any contract, agreement or understanding required to be disclosed herein.

     

    Set forth on Schedule C annexed hereto (“Schedule C”) is the name and present principal occupation or employment, principal business address and citizenship of the executive officers and directors of Ault Life Sciences Fund, LLC. To the best of the Reporting Persons’ knowledge, except as otherwise set forth herein, none of the persons listed in Schedule C beneficially owns any securities of the Issuer or is a party to any contract, agreement or understanding required to be disclosed herein.

     

    Set forth on Schedule D annexed hereto (“Schedule D”) is the name and present principal occupation or employment, principal business address and citizenship of the executive officers and directors of Digital Power Lending, LLC. To the best of the Reporting Persons’ knowledge, except as otherwise set forth herein, none of the persons listed in Schedule D beneficially owns any securities of the Issuer or is a party to any contract, agreement or understanding required to be disclosed herein.

     

    Set forth on Schedule E annexed hereto (“Schedule E”) is the name and present principal occupation or employment, principal business address and citizenship of the executive officers and directors of Ault Alpha LP. To the best of the Reporting Persons’ knowledge, except as otherwise set forth herein, none of the persons listed in Schedule D beneficially owns any securities of the Issuer or is a party to any contract, agreement or understanding required to be disclosed herein.

     

    (b)       The principal business address of Messrs. Ault, Horne and Cragun is c/o BitNile Holdings, Inc., 11411 Southern Highlands Parkway, Suite 240, Las Vegas, Nevada 89141. The principal business address of Mr. Nisser is c/o BitNile Holdings, Inc., 100 Park Avenue, 16th Floor, Suite 1658A, New York, NY 10017. The principal business address of Mr. Katzoff is c/o Alzamend Neuro, Inc., 3500 Lenox Rd. NE, Suite 1500, Atlanta, GA 30326. The principal business address of BitNile Holdings, Inc. is 11411 Southern Highlands Parkway, Suite 240, Las Vegas, Nevada 89141. The principal business address of each of Ault Life Sciences, Inc., Ault Life Sciences Fund, LLC and Digital Power Lending, LLC is 940 South Coast Drive, Suite 200, Costa Mesa, CA 92626. The principal business address of Ault Alpha LP is 11411 Southern Highlands Parkway, Suite 330, Las Vegas, Nevada 89141.

     

    (c)       The principal occupation of Mr. Ault is serving as the Executive Chairman of BitNile Holdings, Inc. The principal occupation of Mr. Horne is serving as the Chief Executive Officer of BitNile Holdings, Inc. The principal occupation of Mr. Nisser is serving as the President and General Counsel of BitNile Holdings, Inc. The principal occupation of Mr. Cragun is serving as the Chief Financial Officer of BitNile Holdings, Inc. The principal occupation of Mr. Katzoff is serving as the Chief Operating Officer of the Issuer.

     

     13 
     

     

    BitNile Holdings, Inc. is a diversified holding company pursuing growth by acquiring undervalued businesses and disruptive technologies with a global impact. Through its wholly and majority-owned subsidiaries and strategic investments, BitNile Holdings, Inc. owns and operates a data center at which it mines Bitcoin and provides mission-critical products that support a diverse range of industries, including defense/aerospace, industrial, automotive, telecommunications, medical/biopharma and textiles The principal business of Ault Life Sciences, Inc., Ault Life Sciences Fund, LLC, Digital Power Lending, LLC and Ault Alpha LP is investing in securities.

     

    (d)       No Reporting Person nor any person listed in Schedules A through E has, during the last five years, been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors).

     

    (e)       No Reporting Person nor any person listed in Schedules A through E has, during the last five years, been party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.

     

    (f)        BitNile Holdings, Inc., Ault Life Sciences, Inc., Ault Life Sciences Fund, LLC and Ault Alpha LP are organized under the laws of the State of Delaware. Digital Power Lending, LLC is organized under the laws of the State of California. Messrs. Ault, Horne, Cragun and Katzoff are citizens of the United States of America. Mr. Nisser is a citizen of Sweden.

     

    Item 3.Source and Amount of Funds or Other Consideration.

     

    The securities of the Issuer purchased by each of BitNile Holdings, Inc., Ault Life Sciences, Inc., Ault Life Sciences Fund, LLC, Digital Power Lending, LLC and Ault Alpha LP were purchased with working capital. The Shares purchased by Mr. Katzoff were purchased with personal funds. The stock options owned by Messrs. Ault, Horne, Nisser, Cragun and Katzoff were awarded to them in their capacities as officers and/or directors of the Issuer. The aggregate purchase price of the warrants currently exercisable into 16,667 Shares owned directly by BitNile Holdings, Inc. is approximately $0. The aggregate purchase price of the 14,942,984 Shares directly owned by Ault Life Sciences, Inc. is approximately $7,970. The aggregate purchase price of the 10,000,000 Shares and warrants currently exercisable into 5,000,000 Shares owned directly by Ault Life Sciences Fund, LLC is approximately $15,000,000. The aggregate purchase price of the 9,666,667 Shares, warrants currently exercisable (subject to beneficial ownership limitations contained therein) into 3,333,333 Shares, and call options (right to buy) currently exercisable into 17,000 Shares owned directly by Digital Power Lending, LLC is approximately $22,823,852. The aggregate purchase price of the 18,000 Shares and warrants currently exercisable into 9,000 Shares owned directly by Mr. Katzoff is approximately $27,000. The aggregate purchase price of the 225,000 Shares owned directly by Ault Alpha LP is approximately $237,100.

     

    Item 5.Interest in Securities of the Issuer.

     

    The aggregate percentage of Shares reported owned by each Reporting Person is based upon 93,019,290 Shares outstanding, which is the total number of Shares outstanding as of April 27, 2022 as reported by the Issuer to the Reporting Persons.

     

     14 
     

     

    A.Milton C. Ault, III

     

    (a) As of the close of business on April 27, 2022, Mr. Ault may be deemed to beneficially own 42,368,318 Shares, consisting of (i) 16,667 Shares underlying currently exercisable warrants held by BitNile Holdings, Inc., (ii) 14,942,984 Shares held by Ault Life Sciences, Inc., (iii) 10,000,000 Shares held by Ault Life Sciences Fund, LLC, (iv) 5,000,000 Shares underlying currently exercisable warrants held by Ault Life Sciences Fund, LLC, (v) 9,666,667 Shares held by Digital Power Lending, LLC, (vi) 225,000 Shares held by Ault Alpha LP, and (vii) 17,000 Shares underlying currently exercisable call options (right to buy) held by Digital Power Lending, LLC. This excludes 3,333,333 Shares underlying currently exercisable warrants held by Digital Power Lending, LLC due to a beneficial ownership blocker limitation provision contained therein. Mr. Ault may be deemed to beneficially own the Shares beneficially owned by BitNile Holdings, Inc., Ault Life Sciences, Inc., Ault Life Sciences Fund, LLC Digital Power Lending, LLC and Ault Alpha LP by virtue of his relationships with such entities described in Item 2.

     

    Percentage: 43.2%

     

    (b)1. Sole power to vote or direct vote: 2,500,000

    2. Shared power to vote or direct vote: 39,868,318

    3. Sole power to dispose or direct the disposition: 2,500,000

    4. Shared power to dispose or direct the disposition: 39,868,318

     

    (c)Mr. Ault has not entered into any transactions in the Shares during the past sixty days.

     

    B.William B. Horne

     

    (a) As of the close of business on April 27, 2022, Mr. Horne may be deemed to beneficially own 2,661,458 Shares, consisting of (i) 500,000 Shares and (ii) 2,161,458 Shares underlying stock options currently exercisable or exercisable within 60 days.

     

    Percentage: 2.8%

     

    (b) 1. Sole power to vote or direct vote: 2,661,458

    2. Shared power to vote or direct vote: 0

    3. Sole power to dispose or direct the disposition: 2,661,458

    4. Shared power to dispose or direct the disposition: 0

     

    (c)Mr. Horne has not entered into any transactions in the Shares during the past sixty days.

     

    C.Henry C.W. Nisser

     

    (a) As of the close of business on April 27, 2022, Mr. Nisser may be deemed to beneficially own 963,542 Shares, consisting of Shares underlying stock options currently exercisable or exercisable within 60 days.

     

    Percentage: 1.0%

     

    (b) 1. Sole power to vote or direct vote: 963,542

    2. Shared power to vote or direct vote: 0

    3. Sole power to dispose or direct the disposition: 963,542

    4. Shared power to dispose or direct the disposition: 0

     

    (c)Mr. Nisser has not entered into any transactions in the Shares during the past sixty days.

     

     15 
     

     

    D.Kenneth S. Cragun

     

    (a) As of the close of business on April 27, 2022, Mr. Cragun may be deemed to beneficially own 1,312,500 Shares, consisting of Shares underlying stock options currently exercisable or exercisable within 60 days.

     

    Percentage: 1.4%

     

    (b) 1. Sole power to vote or direct vote: 1,312,500

    2. Shared power to vote or direct vote: 0

    3. Sole power to dispose or direct the disposition: 1,312,500

    4. Shared power to dispose or direct the disposition: 0

     

    (c)Mr. Cragun has not entered into any transactions in the Shares during the past sixty days.

     

    E.David J. Katzoff

     

    (a) As of the close of business on April 27, 2022, Mr. Katzoff may be deemed to beneficially own 1,079,083 Shares, consisting of (i) 18,000 Shares held directly by him, (ii) 9,000 Shares underlying currently exercisable warrants and (iii) 1,052,083 Shares underlying stock options currently exercisable or exercisable within 60 days.

     

    Percentage: 1.2%

     

    (b) 1. Sole power to vote or direct vote: 1,079,083

    2. Shared power to vote or direct vote: 0

    3. Sole power to dispose or direct the disposition: 1,079,083

    4. Shared power to dispose or direct the disposition: 0

     

    (c)Mr. Katzoff has not entered into any transactions in the Shares during the past sixty days.

     

    F. BitNile Holdings, Inc.

     

    (a) As of the close of business on April 27, 2022, BitNile Holdings, Inc. may be deemed to beneficially own 9,700,334 Shares, consisting of (i) 16,667 Shares underlying currently exercisable warrants held directly by it, (ii) 9,666,667 Shares held by Digital Power Lending, LLC and (iii) 17,000 Shares underlying currently exercisable call options (right to buy) held by Digital Power Lending, LLC. This excludes 3,333,333 Shares underlying currently exercisable warrants held by Digital Power Lending, LLC due to a beneficial ownership blocker limitation provision contained therein. BitNile Holdings, Inc. may be deemed to beneficially own the Shares beneficially owned by Digital Power Lending, LLC by virtue of its relationship with such entity described in Item 2.

     

    Percentage: 10.4%

     

     16 
     

     

    (b)1. Sole power to vote or direct vote: 16,667

    2. Shared power to vote or direct vote: 9,683,667

    3. Sole power to dispose or direct the disposition: 16,667

    4. Shared power to dispose or direct the disposition: 9,683,667

     

    (c) BitNile Holdings, Inc. has not entered into any transactions in the Shares during the past sixty days.

     

    G.Ault Life Sciences, Inc.

     

    (a) As of the close of business on April 27, 2022, Ault Life Sciences, Inc. may be deemed to beneficially own 14,942,984 Shares held directly by it.

     

    Percentage: 16.1%

     

    (b)1. Sole power to vote or direct vote: 0

    2. Shared power to vote or direct vote: 14,942,984

    3. Sole power to dispose or direct the disposition: 0

    4. Shared power to dispose or direct the disposition: 14,942,984

     

    (c) Ault Life Sciences, Inc. has not entered into any transactions in the Shares during the past sixty days, except that on March 4, 2022, Ault Life Sciences, Inc. disposed of 57,016 Shares that were transferred in settlement of an aggregate of $85,500 of debt and obligations owed by Ault & Company, Inc.

     

    H.Ault Life Sciences Fund, LLC

     

    (a) As of the close of business on April 27, 2022, Ault Life Sciences Fund, LLC may be deemed to beneficially own 15,000,000 Shares, consisting of (i) 10,000,000 Shares held directly by it and (ii) 5,000,000 Shares underlying currently exercisable warrants.

     

    Percentage: 15.3%

     

    (b)1. Sole power to vote or direct vote: 0

    2. Shared power to vote or direct vote: 15,000,000

    3. Sole power to dispose or direct the disposition: 0

    4. Shared power to dispose or direct the disposition: 15,000,000

     

    (c)Ault Life Sciences Fund, LLC has not entered into any transactions in the Shares during the past sixty days.

     

    I.Digital Power Lending, LLC

     

    (a) As of the close of business on April 27, 2022, Digital Power Lending, LLC may be deemed to beneficially own 9,683,667 Shares, consisting of (i) 9,666,667 Shares held directly by it and (ii) 17,000 Shares underlying currently exercisable call options (right to buy). This excludes 3,333,333 Shares underlying currently exercisable warrants held directly by it due to a beneficial ownership blocker limitation provision contained therein.

     

    Percentage: 10.4%

     

     17 
     

     

    (b)1. Sole power to vote or direct vote: 0

    2. Shared power to vote or direct vote: 9,683,667

    3. Sole power to dispose or direct the disposition: 0

    4. Shared power to dispose or direct the disposition: 9,683,667

     

    (c) The transactions in the Shares by Digital Power Lending, LLC during the past sixty days are set forth in Schedule F and are incorporated herein by reference.

     

    J. Ault Alpha LP

     

    (a) As of the close of business on April 27, 2022, Ault Alpha LP may be deemed to beneficially own 225,000 Shares, consisting of Shares held directly by it.

     

    Percentage: Less than 1%

     

    (b) 1. Sole power to vote or direct vote: 0

    2. Shared power to vote or direct vote: 225,000

    3. Sole power to dispose or direct the disposition: 0

    4. Shared power to dispose or direct the disposition: 225,000

     

    (c) The transactions in the Shares by Ault Alpha LP during the past sixty days are set forth in Schedule G and are incorporated herein by reference.

     

    The filing of this Amendment No. 2 shall not be deemed an admission that the Reporting Persons are, for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, the beneficial owners of any securities of the Issuer that he or it does not directly own. Each of the Reporting Persons specifically disclaims beneficial ownership of the securities reported herein that he or it does not directly own.

     

    (d)No person other than the Reporting Persons is known to have the right to receive, or the power to direct the receipt of dividends from, or proceeds from the sale of, the Shares.

     

    (e)Not applicable.

     

    Item 7. Material to be Filed as Exhibits.

     

    99.1 Joint Filing Agreement by and among Milton C. Ault, III, William B. Horne, Henry C.W. Nisser, Kenneth S. Cragun, David Katzoff, BitNile Holdings, Inc., Ault Life Sciences, Inc., Ault Life Sciences Fund, LLC, Digital Power Lending, LLC, and Ault Alpha LP, dated April 28, 2022.

     

    99.2 Securities Purchase Agreement dated April 30, 2019, by and between the Issuer and Ault Life Sciences Fund, LLC (incorporated by reference to Exhibit 4.2 of Form 1-A/A filed with the SEC on February 4, 2020).

     

    99.3 Securities Purchase Agreement dated March 9, 2021, by and between the Issuer and Digital Power Lending, LLC (incorporated by reference to Exhibit 6.1 of Form 1-U/A filed with the SEC on May 7, 2021).

     

    99.4 Board Letter Agreement, dated May 6, 2021, by and between the Issuer and Milton C. Ault, III (incorporated by reference to Exhibit 10.17 of Form S-1/A filed with the SEC on May 25, 2021).

     

     18 
     

     

    SIGNATURES

     

    After reasonable inquiry and to the best of his knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

     

    Dated: April 28, 2022

     

        BITNILE HOLDINGS, INC.

    /s/ Milton C. Ault, III

         
    MILTON C. AULT, III   By:

    /s/ Milton C. Ault, III

          Name: Milton C. Ault, III
          Title: Executive Chairman

     

        AULT LIFE SCIENCES, INC.

    /s/ William B. Horne

         
    WILLIAM B. HORNE   By:

    /s/ Milton C. Ault, III

          Name: Milton C. Ault, III
          Title: Chief Executive Officer

     

        AULT LIFE SCIENCES FUND, LLC

    /s/ Henry C.W. Nisser

         
    HENRY C.W. NISSER   By:

    /s/ Milton C. Ault, III

          Name: Milton C. Ault, III
          Title: Managing Member

     

        AULT ALPHA LP

    /s/ Kenneth S. Cragun

         
    KENNETH S. CRAGUN   By:

    /s/ Milton C. Ault, III

          Name: Milton C. Ault, III
          Title: Manager of Ault Alpha GP LLC, the general partner

     

        DIGITAL POWER LENDING, LLC

    /s/ David J. Katzoff

         
    DAVID J. KATZOFF   By:

    /s/ David J. Katzoff

          Name: David J. Katzoff
          Title: Manager

     

     19 
     

     

    SCHEDULE A

     

    Officers and Directors of BitNile Holdings, Inc.

     

    Name and Position Principal Occupation Principal Business Address Citizenship

    Milton C. Ault, III

    Executive Chairman

    Executive Chairman of BitNile Holdings, Inc. c/o BitNile Holdings, Inc. 11411 Southern Highlands Parkway, Suite 240, Las Vegas, NV 89141 USA

    William B. Horne

    Chief Executive Officer and Director

    Chief Executive Officer of BitNile Holdings, Inc. c/o BitNile Holdings, Inc. 11411 Southern Highlands Parkway, Suite 240, Las Vegas, NV 89141 USA

    Henry C.W. Nisser

    President, General Counsel and Director

    President and General Counsel of BitNile Holdings, Inc. c/o BitNile Holdings, Inc. 100 Park Avenue, 16th Floor, Suite 1658A, New York, NY 10017 Sweden

    Kenneth Cragun

    Chief Financial Officer

    Chief Financial Officer of BitNile Holdings, Inc. c/o BitNile Holdings, Inc. 11411 Southern Highlands Parkway, Suite 240, Las Vegas, NV 89141 USA

    Howard Ash

    Independent Director

    Chairman of Claridge Management c/o BitNile Holdings, Inc. 11411 Southern Highlands Parkway, Suite 240, Las Vegas, NV 89141 USA

    Jeffrey A. Bentz

    Independent Director

    President of North Star Terminal & Stevedore Company c/o BitNile Holdings, Inc. 11411 Southern Highlands Parkway, Suite 240, Las Vegas, NV 89141 USA

    Robert O. Smith

    Independent Director

    Independent Executive Consultant c/o BitNile Holdings, Inc. 11411 Southern Highlands Parkway, Suite 240, Las Vegas, NV 89141 USA

    Moti Rosenberg

    Independent Director

    Independent Consultant c/o BitNile Holdings, Inc. 11411 Southern Highlands Parkway, Suite 240, Las Vegas, NV 89141 Israel

     

     20 
     

     

    SCHEDULE B

     

    Officers and Directors of Ault Life Sciences, Inc.

     

    Name and Position Principal Occupation Principal Business Address Citizenship

    Milton C. Ault, III

    Chief Executive Officer and Chairman

    Executive Chairman of BitNile Holdings, Inc. c/o BitNile Holdings, Inc. 11411 Southern Highlands Parkway, Suite 240, Las Vegas, NV 89141 USA

    William B. Horne

    Chief Financial Officer and Director

    Chief Executive Officer of BitNile Holdings, Inc. c/o BitNile Holdings, Inc. 11411 Southern Highlands Parkway, Suite 240, Las Vegas, NV 89141 USA

    Henry C.W. Nisser

    President and Director

    President and General Counsel of BitNile Holdings, Inc. c/o BitNile Holdings, Inc. 100 Park Avenue, 16th Floor, Suite 1658A, New York, NY 10017 Sweden

    Kenneth Cragun

    Chief Accounting Officer

    Chief Financial Officer of BitNile Holdings, Inc. c/o BitNile Holdings, Inc. 11411 Southern Highlands Parkway, Suite 240, Las Vegas, NV 89141 USA

    Brittany Nerpin

    Executive Vice President of Global Business Development

    Executive Vice President of Global Business Development of Ault Life Sciences, Inc. c/o Ault Life Sciences, Inc. 940 South Coast Drive, Suite 200, Costa Mesa, CA 92626 USA

     

     21 
     

     

    SCHEDULE C

     

    Officers and Directors of Ault Life Sciences Fund, LLC

     

    Name and Position Principal Occupation Principal Business Address Citizenship

    Milton C. Ault, III

    Managing Member

    Executive Chairman of BitNile Holdings, Inc. c/o BitNile Holdings, Inc. 11411 Southern Highlands Parkway, Suite 240, Las Vegas, NV 89141 USA

     

     22 
     

     

    SCHEDULE D

     

    Officers and Directors of Digital Power Lending, LLC

     

    Name and Position Principal Occupation Principal Business Address Citizenship

    David J. Katzoff

    Manager

    Chief Operating Officer of Alzamend Neuro, Inc. c/o Alzamend Neuro, Inc., 3500 Lenox Rd. NE, Suite 1500, Atlanta, GA 30326 USA

     

     23 
     

     

    SCHEDULE E

     

    Officers and Directors of Ault Alpha LP

     

    Name and Position Principal Occupation Principal Business Address Citizenship

    Milton C. Ault, III

    Manager of Ault Alpha GP LLC, the general partner

    Executive Chairman of BitNile Holdings, Inc. c/o BitNile Holdings, Inc. 11411 Southern Highlands Parkway, Suite 240, Las Vegas, NV 89141 USA

     

     24 
     

     

    SCHEDULE F

     

    Transactions in the Shares of Common Stock Within the Last Sixty Days

     

    Digital Power Lending, LLC

     

    Nature of the
    Transaction
    Shares of Common
    Stock Purchased/(Sold)
    Price Per Share ($) Date of
    Purchase/Sale
    Purchase of Common Stock 2,666,667 1.50 04/26/2022

     

    Transactions in Warrants Within the Last Sixty Days

     

    Digital Power Lending, LLC

     

    Nature of the
    Transaction
    Number of
    Shares
    Underlying
    Warrant
    Warrant
    Purchase Price
    ($)

    Expiration
    Date

    Exercise
    Price ($)

    Date of Purchase/Sale
    Purchase of Common Stock Warrant 1,333,333 0.00 (received as additional consideration for purchase of common stock)

    04/26/2027

    3.00

    04/26/2022

     

     

     25 
     

     

    SCHEDULE G

     

    Transactions in the Shares of Common Stock Within the Last Sixty Days

     

    Ault Alpha LP

     

    Nature of the Transaction Shares of Common Stock Purchased/(Sold) Price Per Share ($) Date of Purchase/Sale
    Purchase of Common Stock 100,000 1.1045 03/18/2022
    Purchase of Common Stock 50,000 1.1265 04/11/2022
    Purchase of Common Stock 75,000 0.9378 04/22/2022

     

     

    26

     

     

     

    Get the next $ALZN alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $ALZN

    DatePrice TargetRatingAnalyst
    10/1/2021$8.00Buy
    Ascendiant Capital Markets
    More analyst ratings

    $ALZN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Ault Milton C Iii sold $6,196 worth of shares (1,224 units at $5.06), decreasing direct ownership by 0.59% to 1,843 units (SEC Form 4)

      4 - Alzamend Neuro, Inc. (0001677077) (Issuer)

      5/14/25 5:00:07 PM ET
      $ALZN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Horne William B. bought $3,285 worth of shares (3,334 units at $0.99), increasing direct ownership by 13% to 30,000 units (SEC Form 4)

      4 - Alzamend Neuro, Inc. (0001677077) (Issuer)

      3/27/25 7:30:10 AM ET
      $ALZN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Ault Milton C Iii bought $2,969 worth of shares (2,905 units at $1.02) (SEC Form 4)

      4 - Alzamend Neuro, Inc. (0001677077) (Issuer)

      3/25/25 4:30:07 PM ET
      $ALZN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ALZN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Ascendiant Capital Markets initiated coverage on Alzamend Neuro with a new price target

      Ascendiant Capital Markets initiated coverage of Alzamend Neuro with a rating of Buy and set a new price target of $8.00

      10/1/21 7:11:54 AM ET
      $ALZN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ALZN
    SEC Filings

    See more
    • Amendment: SEC Form 144/A filed by Alzamend Neuro Inc.

      144/A - Alzamend Neuro, Inc. (0001677077) (Subject)

      7/11/25 7:15:38 PM ET
      $ALZN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Alzamend Neuro Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits

      8-K - Alzamend Neuro, Inc. (0001677077) (Filer)

      7/9/25 4:30:40 PM ET
      $ALZN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 144 filed by Alzamend Neuro Inc.

      144 - Alzamend Neuro, Inc. (0001677077) (Subject)

      5/9/25 7:49:16 PM ET
      $ALZN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ALZN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Horne William B. bought $3,285 worth of shares (3,334 units at $0.99), increasing direct ownership by 13% to 30,000 units (SEC Form 4)

      4 - Alzamend Neuro, Inc. (0001677077) (Issuer)

      3/27/25 7:30:10 AM ET
      $ALZN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Ault Milton C Iii bought $2,969 worth of shares (2,905 units at $1.02) (SEC Form 4)

      4 - Alzamend Neuro, Inc. (0001677077) (Issuer)

      3/25/25 4:30:07 PM ET
      $ALZN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Financial Officer Katzoff David J bought $5,048 worth of shares (5,000 units at $1.01), increasing direct ownership by 926% to 5,540 units (SEC Form 4)

      4 - Alzamend Neuro, Inc. (0001677077) (Issuer)

      3/24/25 7:30:07 AM ET
      $ALZN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ALZN
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Alzamend Neuro Announces Final Closing of $5 Million Private Placement Months Ahead of Schedule

      ATLANTA, June 16, 2025 (GLOBE NEWSWIRE) -- Alzamend Neuro, Inc. (NASDAQ:ALZN) ("Alzamend"), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer's disease ("Alzheimer's"), bipolar disorder ("BD"), major depressive disorder ("MDD") and post-traumatic stress disorder ("PTSD"), today announced that it has completed the final closing of its $5 million private placement. As previously reported, on February 28, 2025, Alzamend entered into a Securities Purchase & Exchange Agreement (the "Agreement") with a sophisticated investor (the "Investor"), pursuant to which Alzamend agreed to sell to the Investor up to 500 shares of Series C Conver

      6/16/25 8:00:00 AM ET
      $ALZN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Alzamend Neuro Announces Dosing of First Patient in its Phase II Clinical Trial of AL001 "Lithium in Brain" Study Taking Place at Massachusetts General Hospital

      Topline data expected by year endHead-to-head studies of AL001 versus a marketed lithium carbonate product will be conducted for comparisons of lithium blood and brain/brain-structure pharmacokinetics in healthy subjects ATLANTA, May 29, 2025 (GLOBE NEWSWIRE) -- Alzamend Neuro, Inc. (NASDAQ:ALZN) ("Alzamend"), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer's disease ("Alzheimer's"), bipolar disorder ("BD"), major depressive disorder ("MDD") and post-traumatic stress disorder ("PTSD"), today announced the dosing of the first patient of its first Phase II clinical study of AL001, in healthy human subjects. This study follows th

      5/29/25 8:00:00 AM ET
      $ALZN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Alzamend Neuro Enrolls First Patient in its Phase II Clinical Trial of AL001 "Lithium in Brain" Study Taking Place at Massachusetts General Hospital

      Topline data expected by year endHead-to-head studies of AL001 versus a marketed lithium carbonate product will be conducted for comparisons of lithium blood and brain/brain-structure pharmacokinetics in healthy subjects ATLANTA, May 19, 2025 (GLOBE NEWSWIRE) -- Alzamend Neuro, Inc. (NASDAQ:ALZN) ("Alzamend"), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer's disease ("Alzheimer's"), bipolar disorder ("BD"), major depressive disorder ("MDD") and post-traumatic stress disorder ("PTSD"), today announced the enrollment of the first patient of its first Phase II clinical study of AL001, in healthy human subjects. This study follow

      5/19/25 8:00:00 AM ET
      $ALZN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ALZN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D/A filed by Alzamend Neuro Inc. (Amendment)

      SC 13D/A - Alzamend Neuro, Inc. (0001677077) (Subject)

      2/2/24 4:38:42 PM ET
      $ALZN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by Alzamend Neuro Inc. (Amendment)

      SC 13D/A - Alzamend Neuro, Inc. (0001677077) (Subject)

      1/25/24 5:21:29 PM ET
      $ALZN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by Alzamend Neuro Inc. (Amendment)

      SC 13D/A - Alzamend Neuro, Inc. (0001677077) (Subject)

      11/15/22 4:30:13 PM ET
      $ALZN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ALZN
    Leadership Updates

    Live Leadership Updates

    See more
    • Alzamend Neuro Appoints Dr. Terri Hunter to Its Scientific Advisory Board

      Alzamend Neuro, Inc. (NASDAQ:ALZN) ("Alzamend"), an early clinical-stage biopharmaceutical company focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, today announced the appointment of Dr. Terri Hunter, Ph.D., a Technology Transfer Specialist, to its Scientific Advisory Board. During her tenure at the University of South Florida ("USF"), Dr. Hunter was responsible for managing the patent portfolio associated with Alzamend's two product candidates, AL001 and AL002. AL001 is a novel lithium-delivery system; it is a lithium-salicylate-L-proline engineered ionic co-crystal under development as an oral treatment for patients with demen

      4/4/22 8:00:00 AM ET
      $ALZN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ALZN
    Financials

    Live finance-specific insights

    See more
    • BitNile Holdings Reports Third Quarter 2022 Financial Results, Including Revenue of $100 Million for the Nine Months Ended September 30, 2022, up 124% from the Prior Year's Nine-Month Period

      BitNile Holdings, Inc. (NYSE:NILE), a diversified holding company ("BitNile" or the "Company"), reported its financial results for the third quarter ended September 30, 2022 on its Form 10-Q filed with the Securities and Exchange Commission. Third quarter 2022 highlights include: Total assets of $610.9 million as of September 30, 2022; Positive working capital of $25.7 million as of September 30, 2022; Cash and cash equivalents of $10.1 million as of September 30, 2022; Revenue from cryptocurrency mining of $3.9 million, compared to $0.3 million in the prior third fiscal quarter; Revenue from the Company's majority owned subsidiary, The Singing Machine Company, Inc. (NASDAQ:MICS)

      11/21/22 7:27:00 PM ET
      $ALZN
      $MICS
      $NILE
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Diversified Electronic Products
      Consumer Staples
    • BitNile Holdings Reports Second Quarter 2022 Financial Results

      BitNile Holdings, Inc. (NYSE:NILE), a diversified holding company ("BitNile" or the "Company"), reported its financial results for the second quarter ended June 30, 2022 on its Form 10-Q filed with the Securities and Exchange Commission. Second quarter 2022 highlights include: Total assets of $596.3 million as of June 30, 2022; Positive working capital of $51.4 million as of June 30, 2022; Cash and cash equivalents of $24.1 million as of June 30, 2022; Revenue from cryptocurrency mining of $4.0 million, compared to $0.3 million in the prior second fiscal quarter; Revenue from hotel operations of $4.6 million, compared to $0 in the prior second fiscal quarter; Revenue from lendi

      8/23/22 6:30:00 AM ET
      $ALZN
      $NILE
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Military/Government/Technical
      Industrials
    • BitNile Holdings Reports 2021 Year-End Results

      The Company Grows Revenue by 120% to $52 Million and Ends the Year with $490 Million in Assets BitNile Holdings, Inc. (NYSE:NILE), a diversified holding company ("BitNile" or the "Company") today announced its financial results for the year ended December 31, 2021 contained within its Form 10‑K filed with the Securities and Exchange Commission. Year ended December 31, 2021 highlights: Revenue of $52.4 million, an increase of 120% from $23.9 million in the prior fiscal year; Revenue from lending and trading activities of $16.9 million due to the allocation of capital to Digital Power Lending, LLC ("DP Lending"); Revenue from trading activities during the year ended December 31, 2021

      4/18/22 6:30:00 AM ET
      $ALZN
      $NILE
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Military/Government/Technical
      Industrials